Clinical trial · Observational
Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
NCT05212779CI-TRIAL-00073505unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Blood samples and Tumor tissue will be collected at certain timepoints and will be tested.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epithelial Ovarian Cancer | Ovarian Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Altera Testing | Diagnostic Test | — | UNRESOLVED |
| Signatera testing | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Females with Stage II-IV epithelial ovarian cancer
- description
- All patients, as participation requirements in this study, are required to have blood drawn at the completion of their adjuvant treatment. Blood sample should be collected within 6 weeks of receiving the last cycle of adjuvant chemotherapy. Other optional time points which will be encouraged but not required: 1. After debulking surgery 2. Serial draws every 3 months while on maintenance or surveillance.
- interventionNames
- Diagnostic Test: Signatera testing
- Diagnostic Test: Altera Testing
Primary outcomes (1)
- measure
- To assess the effect of a negative Signatera MRD test on progression free survival (PFS) compared to Signatera MRD testing positive patients.
- timeFrame
- Signatera MRD testing done within 6 weeks of finishing adjuvant therapy
- description
- The Signatera MRD test measures the amount of circulating tumor DNA(ctDNA). We seek to assess the effect of a negative versus positive test on PFS. PFS will be measured in months from the time of last platinum adjuvant chemotherapy to objective disease progression on imaging according to RECIST 1.1 or death from any cause
Secondary outcomes (10)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 95 Years
Show eligibility criteria text
Inclusion Criteria: Clinical diagnosis of epithelial ovarian cancer stage II-IV Exclusion Criteria: Insufficient tumor to perform Signatera testing; Inability to provide consent for the trial
References
Publications (0)
Data not yet available
No reference posted for this study.